Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)
Abstract
Background: Chemotherapeutic drug efflux via the P-glycoprotein (P-gp) transporter encoded by the MDR1/ABCB1 gene is a significant cause of drug resistance in numerous malignancies, including acute leukemias, especially in older patients with acute myeloid leukemia (AML). Therefore, the P-gp modulators that block P-gp-mediated drug efflux have been developed, and used in combination with standard chemotherapy. In this paper, the capacity of zosuquidar, a specific P-gp modulator, to reverse chemoresistance was examined in both leukemia cell lines and primary AML blasts. Methods:The transporter protein expressions were analyzed by flow cytometry using their specific antibodies. The protein functionalities were assessed by the uptake of their fluorescence substrates in presence or absence their specific modulators. The drug cytotoxicity was evaluated by MTT test. Results: Zosuquidar completely or partially restored drug sensitivity in all P-gp-expressing leukemia cell lines tested and enhanced the cytotoxicity of anthracyclines (daunorubicin, idarubicin, mitoxantrone) and gemtuzumab ozogamicin (Mylotarg) in primary AML blasts with active P-gp. In addition, P-gp inhibition by zosuquidar was found to be more potent than cyclosporine A in cells with highly active P-gp. Conclusion: These in vitro studies suggest that zosuquidar may be an effective adjunct to cytotoxic chemotherapy for AML patients whose blasts express P-gp, especially for older patients.
Related
- Expressing glycan motifs as a containment order increases sensitivity and uncovers motif redistributions
- TRPV1-expressing neurons are dispensable for photophobia: evidence from a novel mouse light sensitivity assay
- Double functionalized Sindbis E2 glycoprotein modifies Sindbis tropism favouring infection of α5β1⁺ glioblastoma cells
- The Cytosolic Zinc Finger Domain Structure of the CCHFV Glycoprotein n Is Maintained in Its Membrane-Bound Form
- Phenuivirus glycoprotein Gc domain is a conserved target of cross-functional monoclonal antibodies
BibTeX
@article{tang2026zosuquidar,
title = {{Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)}},
author = {Ruoping Tang and Anne-Marie Faussat and Jean-Yves Perrot and Zora Marjanociv and Simy Cohen and Thomas Storme and H. Morjani and Olivier Legrand and Jean-Pierre Marie},
journal = {BMC Cancer},
year = {2026},
month = sep,
doi = {10.1186/1471-2407-8-51},
url = {https://hal.science/hal-00355913v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)
AU - Ruoping Tang
AU - Anne-Marie Faussat
AU - Jean-Yves Perrot
AU - Zora Marjanociv
AU - Simy Cohen
AU - Thomas Storme
AU - H. Morjani
AU - Olivier Legrand
AU - Jean-Pierre Marie
PY - 2026
DA - 2026/09/15
JO - BMC Cancer
DO - 10.1186/1471-2407-8-51
UR - https://hal.science/hal-00355913v1
AB - Background: Chemotherapeutic drug efflux via the P-glycoprotein (P-gp) transporter encoded by the MDR1/ABCB1 gene is a significant cause of drug resistance in numerous malignancies, including acute leukemias, especially in older patients with acute myeloid leukemia (AML). Therefore, the P-gp modulators that block P-gp-mediated drug efflux have been developed, and used in combination with standard chemotherapy. In this paper, the capacity of zosuquidar, a specific P-gp modulator, to reverse chemoresistance was examined in both leukemia cell lines and primary AML blasts. Methods:The transporter protein expressions were analyzed by flow cytometry using their specific antibodies. The protein functionalities were assessed by the uptake of their fluorescence substrates in presence or absence their specific modulators. The drug cytotoxicity was evaluated by MTT test. Results: Zosuquidar completely or partially restored drug sensitivity in all P-gp-expressing leukemia cell lines tested and enhanced the cytotoxicity of anthracyclines (daunorubicin, idarubicin, mitoxantrone) and gemtuzumab ozogamicin (Mylotarg) in primary AML blasts with active P-gp. In addition, P-gp inhibition by zosuquidar was found to be more potent than cyclosporine A in cells with highly active P-gp. Conclusion: These in vitro studies suggest that zosuquidar may be an effective adjunct to cytotoxic chemotherapy for AML patients whose blasts express P-gp, especially for older patients.
SN - 1471-2407
SN - 1471-2407
ER -